Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2013 - 2026)

Amphastar Pharmaceuticals has reported Non-Current Assets for 14 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 7.57% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $4.1 billion, a 0.77% increase from a year earlier, with the FY2025 full-year figure at $993.3 million, down 4.8% from the prior year.
• Non-Current Assets was $1.1 billion for Q2 2026 at Amphastar Pharmaceuticals, up from $1.0 billion in the prior quarter.
• The five-year high for Non-Current Assets was $1.1 billion in Q2 2026, with the low at $342.5 million in Q3 2022.
• Average Non-Current Assets over 5 years is $837.8 million, with a median of $1.0 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 192.47% in 2023, then fell 4.8% in 2025.
• Over 5 years, Non-Current Assets stood at $363.7 million in 2022, then soared by 181.39% to $1.0 billion in 2023, then grew by 1.96% to $1.0 billion in 2024, then dropped by 4.8% to $993.3 million in 2025, then increased by 12.03% to $1.1 billion in 2026.
• The last three Non-Current Assets figures came in at $1.1 billion (Q2 2026), $1.0 billion (Q1 2026), and $993.3 million (Q4 2025), per Business Quant data.